Abstract
Hepatocellular carcinoma (HCC) is a lethal human malignancy with a very low overall and long-term survival rate. Poor prognostic outcomes are predominantly associated with HCC due to a huge landscape of heterogeneity found in the deadliest disease. However, molecular subtyping of HCC has significantly improved the knowledge of the underlying mechanisms that contribute towards the heterogeneity and progression of the disease. In this review, we have extensively summarized the current information available about molecular classification of HCC. This review can be of great significance for providing the insight information needed for development of novel, efficient and personalized therapeutic options for the treatment of HCC patients globally.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahn S-M, Jang SJ, Shim JH et al (2014) Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 60:1972–1982. https://doi.org/10.1002/hep.27198
Ahn S-M, Haq F, Park I et al (2018) The clinical implications of G1–G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma. BMC Cancer 18:571. https://doi.org/10.1186/s12885-018-4192-1
Birchmeier C, Birchmeier W, Gherardi E, Woude GFV (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–925. https://doi.org/10.1038/nrm1261
Boyault S, Rickman DS, de Reyniès A et al (2006) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets-Boyault-2007-Hepatology-Wiley Online Library. Hepatology 45:42–52. https://doi.org/10.1002/hep.21467
Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Breuhahn K, Vreden S, Haddad R et al (2004) Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res 64:6058–6064. https://doi.org/10.1158/0008-5472.CAN-04-0292
Budhu A, Forgues M, Ye Q-H et al (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10:99–111. https://doi.org/10.1016/j.ccr.2006.06.016
Budhu A, Jia H-L, Forgues M et al (2008) Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47:897–907. https://doi.org/10.1002/hep.22160
Calderaro J, Couchy G, Imbeaud S et al (2017) Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 67:727–738. https://doi.org/10.1016/j.jhep.2017.05.014
Carone C, Olivani A, Dalla Valle R et al (2018) Immune gene expression profile in hepatocellular carcinoma and surrounding tissue predicts time to tumor recurrence. LIC 7:277–294. https://doi.org/10.1159/000486764
Chen C-K, Yang C-Y, Hua K-T et al (2014) Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment. Hepatology 59:974–985. https://doi.org/10.1002/hep.26738
Chen B, Garmire L, Calvisi DF et al (2020a) Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 17:238–251. https://doi.org/10.1038/s41575-019-0240-9
Chen M, Zhang B, Topatana W et al (2020b) Classification and mutation prediction based on histopathology H&E images in liver cancer using deep learning. Npj Precis Oncol 4:1–7. https://doi.org/10.1038/s41698-020-0120-3
Chiang DY, Villanueva A, Hoshida Y et al (2008) Focal gains of vascular endothelial growth factor A and molecular classification of hepatocellular carcinoma. Cancer Res 68:6779–6788. https://doi.org/10.1158/0008-5472.CAN-08-0742
Coulouarn C, Factor VM, Thorgeirsson SS (2008) Transforming growth factor-β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47:2059–2067. https://doi.org/10.1002/hep.22283
Coulouarn C, Cavard C, Rubbia-Brandt L et al (2012) Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways. Carcinogenesis 33:1791–1796. https://doi.org/10.1093/carcin/bgs208
Désert R, Rohart F, Canal F et al (2017) Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Hepatology 66:1502–1518. https://doi.org/10.1002/hep.29254
Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674–687. https://doi.org/10.1038/nrc1934
Finn RS (2013) Emerging targeted strategies in advanced hepatocellular carcinoma. Semin Liver Dis 33:S11–S19. https://doi.org/10.1055/s-0033-1333632
Finn RS, Aleshin A, Dering J et al (2013) Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology 57:1838–1846. https://doi.org/10.1002/hep.26223
Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379:1245–1255. https://doi.org/10.1016/S0140-6736(11)61347-0
Fu Q, Yang F, Xiang T et al (2018) A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy. Sci Rep 8:1–8. https://doi.org/10.1038/s41598-018-26374-9
Fujiwara N, Friedman SL, Goossens N, Hoshida Y (2018) Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 68:526–549. https://doi.org/10.1016/j.jhep.2017.09.016
Galun E (2016) Liver inflammation and cancer: The role of tissue microenvironment in generating the tumor-promoting niche (TPN) in the development of hepatocellular carcinoma. Hepatology 63:354–356. https://doi.org/10.1002/hep.28344
Giannelli G, Villa E, Lahn M (2014) Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma. Cancer Res 74:1890–1894. https://doi.org/10.1158/0008-5472.CAN-14-0243
Giannini EG, Aglitti A, Borzio M et al (2019) Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI.CA cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice. Cancers 11:1689. https://doi.org/10.3390/cancers11111689
Gu J-X, Zhang X, Miao R-C et al (2019) Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma. World J Gastroenterol 25:220–232. https://doi.org/10.3748/wjg.v25.i2.220
Han B, Zheng Y, Wang L et al (2019) A novel microRNA signature predicts vascular invasion in hepatocellular carcinoma. J Cell Physiol 234:20859–20868. https://doi.org/10.1002/jcp.28690
Hirschfield H, Bian CB, Higashi T et al (2018) In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment. Exp Mol Med 50:e419–e419. https://doi.org/10.1038/emm.2017.164
Hodges KB, Cummings OW, Saxena R et al (2010) Clonal origin of multifocal hepatocellular carcinoma. Cancer 116:4078–4085. https://doi.org/10.1002/cncr.25258
Hong Y, Peng Y, Guo ZS et al (2014) Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology 59:1448–1458. https://doi.org/10.1002/hep.26893
Hoshida Y, Villanueva A, Kobayashi M et al (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359:1995–2004. https://doi.org/10.1056/NEJMoa0804525
Hoshida Y, Nijman SMB, Kobayashi M et al (2009) Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69:7385–7392. https://doi.org/10.1158/0008-5472.CAN-09-1089
Hoshida Y, Toffanin S, Lachenmayer A et al (2010) Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 30:35–51. https://doi.org/10.1055/s-0030-1247131
Hoshida Y, Moeini A, Alsinet C et al (2012) Gene signatures in the management of hepatocellular carcinoma. Semin Oncol 39:473–485. https://doi.org/10.1053/j.seminoncol.2012.05.003
Hoshida Y, Villanueva A, Sangiovanni A et al (2013) Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 144:1024–1030. https://doi.org/10.1053/j.gastro.2013.01.021
Hou Y, Guo H, Cao C et al (2016) Single-cell triple omics sequencing reveals genetic, epigenetic, and transcriptomic heterogeneity in hepatocellular carcinomas. Cell Res 26:304–319. https://doi.org/10.1038/cr.2016.23
Hu B, Yang X-B, Sang X-T (2020) Molecular subtypes based on immune-related genes predict the prognosis for hepatocellular carcinoma patients. Int Immunopharmacol. https://doi.org/10.1016/j.intimp.2020.107164
Hyeon J, Ahn S, Lee JJ et al (2013) Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma. Dig Dis Sci 58:1916–1922. https://doi.org/10.1007/s10620-013-2609-x
Ji J, Shi J, Budhu A et al (2009a) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361:1437–1447. https://doi.org/10.1056/NEJMoa0901282
Ji J, Yamashita T, Budhu A et al (2009b) Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM–positive hepatic cancer stem cells. Hepatology 50:472–480. https://doi.org/10.1002/hep.22989
Jiang J, Gusev Y, Aderca I et al (2008) Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 14:419–427. https://doi.org/10.1158/1078-0432.CCR-07-0523
Jopling CL, Yi M, Lancaster AM et al (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309:1577–1581. https://doi.org/10.1126/science.1113329
Kang HJ, Haq F, Sung CO et al (2019) Characterization of hepatocellular carcinoma patients with FGF19 amplification assessed by fluorescence in situ hybridization: a large cohort study. LIC 8:12–23. https://doi.org/10.1159/000488541
Kaposi-Novak P, Lee J-S, Gòmez-Quiroz L et al (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116:1582–1595. https://doi.org/10.1172/JCI27236
Kew MC (2012) Hepatocellular carcinoma in developing countries: prevention, diagnosis and treatment. World J Hepatol 4:99–104. https://doi.org/10.4254/wjh.v4.i3.99
Kim H-S, El-Serag HB (2019) The epidemiology of hepatocellular carcinoma in the USA. Curr Gastroenterol Rep 21:17. https://doi.org/10.1007/s11894-019-0681-x
Knox JJ, Cleary SP, Dawson LA (2015) Localized and systemic approaches to treating hepatocellular carcinoma. JCO 33:1835–1844. https://doi.org/10.1200/JCO.2014.60.1153
Krizhanovsky V, Yon M, Dickins RA et al (2008) Senescence of activated stellate cells limits liver fibrosis. Cell 134:657–667. https://doi.org/10.1016/j.cell.2008.06.049
Kulik L, El-Serag HB (2019) Epidemiology and management of hepatocellular carcinoma. Gastroenterology 156:477-491.e1. https://doi.org/10.1053/j.gastro.2018.08.065
Ladeiro Y, Couchy G, Balabaud C et al (2008) MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47:1955–1963. https://doi.org/10.1002/hep.22256
Laurent-Puig P, Zucman-Rossi J (2006) Genetics of hepatocellular tumors. Oncogene 25:3778–3786. https://doi.org/10.1038/sj.onc.1209547
Lee J-S, Chu I-S, Heo J et al (2004) Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40:667–676. https://doi.org/10.1002/hep.20375
Lee J-S, Heo J, Libbrecht L et al (2006) A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12:410–416. https://doi.org/10.1038/nm1377
Li N, Fu H, Tie Y et al (2009) miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 275:44–53. https://doi.org/10.1016/j.canlet.2008.09.035
Li B, Feng W, Luo O et al (2017) Development and validation of a three-gene prognostic signature for patients with hepatocellular carcinoma. Sci Rep 7:1–13. https://doi.org/10.1038/s41598-017-04811-5
Li W, Wang H, Ma Z et al (2019) Multi-omics analysis of microenvironment characteristics and immune escape mechanisms of hepatocellular carcinoma. Front Oncol. https://doi.org/10.3389/fonc.2019.01019
Liu L, Cao Y, Chen C et al (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851–11858. https://doi.org/10.1158/0008-5472.CAN-06-1377
Liu G-M, Zeng H-D, Zhang C-Y, Xu J-W (2019a) Identification of a six-gene signature predicting overall survival for hepatocellular carcinoma. Cancer Cell Int 19:138. https://doi.org/10.1186/s12935-019-0858-2
Liu X-N, Cui D-N, Li Y-F et al (2019b) Multiple “Omics” data-based biomarker screening for hepatocellular carcinoma diagnosis. World J Gastroenterol 25:4199–4212. https://doi.org/10.3748/wjg.v25.i30.4199
Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312–1327. https://doi.org/10.1002/hep.22506
Llovet JM, Hernandez-Gea V (2014) Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 20:2072–2079. https://doi.org/10.1158/1078-0432.CCR-13-0547
Llovet JM, Schwartz M, Mazzaferro V (2005) Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25:181–200. https://doi.org/10.1055/s-2005-871198
Llovet JM, Di Bisceglie AM, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711. https://doi.org/10.1093/jnci/djn134
Llovet JM, Villanueva A, Lachenmayer A, Finn RS (2015) Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 12:408–424. https://doi.org/10.1038/nrclinonc.2015.103
Luk JM, Burchard J, Zhang C et al (2011) DLK1-DIO3 genomic imprinted MicroRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. J Biol Chem 286:30706–30713. https://doi.org/10.1074/jbc.M111.229831
Miltiadous O, Sia D, Hoshida Y et al (2015) Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. J Hepatol 63:1368–1377. https://doi.org/10.1016/j.jhep.2015.07.025
Mínguez B, Tovar V, Chiang D et al (2009) Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 25:186–194. https://doi.org/10.1097/MOG.0b013e32832962a1
Mínguez B, Hoshida Y, Villanueva A et al (2011) Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 55:1325–1331. https://doi.org/10.1016/j.jhep.2011.02.034
Mo Z, Cao Z, Luo S et al (2020) Novel molecular subtypes associated with 5mC methylation and their role in hepatocellular carcinoma immunotherapy. Front Mol Biosci. https://doi.org/10.3389/fmolb.2020.562441
Moeini A, Torrecilla S, Tovar V et al (2019) An immune gene expression signature associated with development of human hepatocellular carcinoma identifies mice that respond to chemopreventive agents. Gastroenterology. https://doi.org/10.1053/j.gastro.2019.07.028
Montal R, Andreu-Oller C, Bassaganyas L et al (2019) Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. Br J Cancer 121:340–343. https://doi.org/10.1038/s41416-019-0513-7
Munro S, Carr SM, Thangue NBL (2012) Diversity within the pRb pathway: is there a code of conduct? | Oncogene. Oncogene. https://doi.org/10.1038/onc.2011.603
Murakata A, Tanaka S, Mogushi K et al (2011) Gene expression signature of the gross morphology in hepatocellular carcinoma. Ann Surg 253:94. https://doi.org/10.1097/SLA.0b013e3181f9bc00
Nault JC, Mallet M, Pilati C et al (2013a) High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 4:2218. https://doi.org/10.1038/ncomms3218
Nault J-C, Reyniès AD, Villanueva A et al (2013b) A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 145:176–187. https://doi.org/10.1053/j.gastro.2013.03.051
Niu Z-S, Niu X-J, Wang W-H (2016) Genetic alterations in hepatocellular carcinoma: an update. World J Gastroenterol 22:9069–9095. https://doi.org/10.3748/wjg.v22.i41.9069
Ogunwobi OO, Puszyk W, Dong H-J, Liu C (2013) Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma. PLoS ONE 8:e63765. https://doi.org/10.1371/journal.pone.0063765
Okrah K, Tarighat S, Liu B et al (2018) Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology. Npj Precisi Oncol 2:1–11. https://doi.org/10.1038/s41698-018-0068-8
Peng L, Yuan X-Q, Zhang C-Y et al (2018) The emergence of long non-coding RNAs in hepatocellular carcinoma: an update. J Cancer 9:2549–2558. https://doi.org/10.7150/jca.24560
Qiao G, Chen L, Wu J, Li Z (2019) Identification of an eight-gene signature for survival prediction for patients with hepatocellular carcinoma based on integrated bioinformatics analysis. PeerJ 7:e6548. https://doi.org/10.7717/peerj.6548
Qin L (2014) Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies. Front Med 8:24–32. https://doi.org/10.1007/s11684-014-0312-8
Qiu L, Wang T, Ge Q et al (2019) Circular RNA signature in hepatocellular carcinoma. J Cancer 10:3361–3372. https://doi.org/10.7150/jca.31243
Raja A, Park I, Haq F, Ahn S-M (2019) FGF19–FGFR4 signaling in hepatocellular carcinoma. Cells 8:536. https://doi.org/10.3390/cells8060536
Roessler S, Jia H-L, Budhu A et al (2010) A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 70:10202–10212. https://doi.org/10.1158/0008-5472.CAN-10-2607
Schirmacher P, Calvisi DF (2013) Molecular diagnostic algorithms in hepatocellular carcinoma: dead-end street or light at the end of the tunnel? Gastroenterology 145:49–53. https://doi.org/10.1053/j.gastro.2013.05.026
Schmitz KJ, Wohlschlaeger J, Lang H et al (2008) Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 48:83–90. https://doi.org/10.1016/j.jhep.2007.08.018
Schulze K, Imbeaud S, Letouzé E et al (2015) Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47:505–511. https://doi.org/10.1038/ng.3252
Shi Y-M, Li Y-Y, Lin J-Y et al (2019) The discovery of a novel eight-mRNA-lncRNA signature predicting survival of hepatocellular carcinoma patients. J Cell Biochem 120:7539–7550. https://doi.org/10.1002/jcb.28028
Shimada S, Mogushi K, Akiyama Y et al (2019) Comprehensive molecular and immunological characterization of hepatocellular carcinoma. EBioMedicine 40:457–470. https://doi.org/10.1016/j.ebiom.2018.12.058
Sia D, Jiao Y, Martinez-Quetglas I et al (2017) Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology 153:812–826. https://doi.org/10.1053/j.gastro.2017.06.007
Sun Y, Zhang F, Wang L et al (2019) A five lncRNA signature for prognosis prediction in hepatocellular carcinoma. Mol Med Rep 19:5237–5250. https://doi.org/10.3892/mmr.2019.10203
Tan PS, Nakagawa S, Goossens N et al (2016) Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int 36:108–118. https://doi.org/10.1111/liv.12889
Tandon P, Garcia-Tsao G (2009) Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 29:502–510. https://doi.org/10.1111/j.1478-3231.2008.01957.x
Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31:339–346. https://doi.org/10.1038/ng0802-339
Toffanin S, Hoshida Y, Lachenmayer A et al (2011) MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 140:1618-1628.e16. https://doi.org/10.1053/j.gastro.2011.02.009
Tschaharganeh DF, Xue W, Calvisi DF et al (2014) p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell 158:579–592. https://doi.org/10.1016/j.cell.2014.05.051
Ura S, Honda M, Yamashita T et al (2009) Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49:1098–1112. https://doi.org/10.1002/hep.22749
Varnholt H, Drebber U, Schulze F et al (2008) MicroRNA gene expression profile of hepatitis C virus—associated hepatocellular carcinoma. Hepatology 47:1223–1232. https://doi.org/10.1002/hep.22158
Villa E, Critelli R, Lei B et al (2016) Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a Prospective Study. Gut 65:861–869. https://doi.org/10.1136/gutjnl-2014-308483
Villanueva A, Hoshida Y, Battiston C et al (2011) Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 140:1501-1512.e2. https://doi.org/10.1053/j.gastro.2011.02.006
Wang XW, Thorgeirsson SS (2009) Transcriptome analysis of liver cancer: ready for the clinic? J Hepatol 50:1062–1064. https://doi.org/10.1016/j.jhep.2009.02.007
Wang K, Lim HY, Shi S et al (2013) Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology 58:706–717. https://doi.org/10.1002/hep.26402
Wang S, Zhang J-H, Wang H et al (2019) A novel multidimensional signature predicts prognosis in hepatocellular carcinoma patients. J Cell Physiol 234:11610–11619. https://doi.org/10.1002/jcp.27818
Wei R, Huang G-L, Zhang M-Y et al (2013) Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma. Clin Cancer Res 19:4780–4791. https://doi.org/10.1158/1078-0432.CCR-12-2728
Wei L, Delin Z, Kefei Y et al (2019) A classification based on tumor budding and immune score for patients with hepatocellular carcinoma. OncoImmunology. https://doi.org/10.1080/2162402X.2019.1672495
Wheeler DA, Roberts LR (2017) Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169:1327-1341.e23. https://doi.org/10.1016/j.cell.2017.05.046
Woo HG, Lee J-H, Yoon J-H et al (2010) Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res 70:3034–3041. https://doi.org/10.1158/0008-5472.CAN-09-2823
Woo HG, Park ES, Thorgeirsson SS, Kim YJ (2011) Exploring genomic profiles of hepatocellular carcinoma. Mol Carcinog 50:235–243. https://doi.org/10.1002/mc.20691
Wörns M-A, Galle PR (2014) HCC therapies—lessons learned. Nat Rev Gastroenterol Hepatol 11:447–452. https://doi.org/10.1038/nrgastro.2014.10
Wu J, Zhu AX (2011) Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol 4:30. https://doi.org/10.1186/1756-8722-4-30
Xiang Q, Chen W, Ren M et al (2014) Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res 20:2959–2970. https://doi.org/10.1158/1078-0432.CCR-13-2620
Xiang X-H, Yang L, Zhang X et al (2019) Seven-senescence-associated gene signature predicts overall survival for Asian patients with hepatocellular carcinoma. World J Gastroenterol 25:1715–1728. https://doi.org/10.3748/wjg.v25.i14.1715
Xiao Q, Nobre A, Piñeiro P et al (2020) Genetic and epigenetic biomarkers of immune checkpoint blockade response. J Clin Med. https://doi.org/10.3390/jcm9010286
Xie Q, Liu K-D, Hu M-Y, Zhou K (2001) SF/HGF-c-Met autocrine and paracrine promote metastasis of hepatocellular carcinoma. World J Gastroenterol 7:816–820. https://doi.org/10.3748/wjg.v7.i6.816
Xu D, Liu X, Wang Y et al (2020) Identification of immune subtypes and prognosis of hepatocellular carcinoma based on immune checkpoint gene expression profile. Biomed Pharmacother 126:109903. https://doi.org/10.1016/j.biopha.2020.109903
Yamashita T, Forgues M, Wang W et al (2008) EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68:1451–1461. https://doi.org/10.1158/0008-5472.CAN-07-6013
Yan J, Zhou C, Guo K et al (2019a) A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma. J Cell Biochem 120:213–223. https://doi.org/10.1002/jcb.27321
Yan Y, Lu Y, Mao K et al (2019b) Identification and validation of a prognostic four-genes signature for hepatocellular carcinoma: integrated ceRNA network analysis. Hepatol Int 13:618–630. https://doi.org/10.1007/s12072-019-09962-3
Yang C, Chen J, Li Y et al (2020a) Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen. Brief Bioinform. https://doi.org/10.1093/bib/bbaa295
Yang C, Huang X, Liu Z et al (2020b) Metabolism-associated molecular classification of hepatocellular carcinoma. Mol Oncol 14:896–913. https://doi.org/10.1002/1878-0261.12639
Ye Q-H, Qin L-X, Forgues M et al (2003) Predicting hepatitis B virus–positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9:416–423. https://doi.org/10.1038/nm843
Yu L-X, Ling Y, Wang H-Y (2018) Role of nonresolving inflammation in hepatocellular carcinoma development and progression. Npj Precis Oncoly 2:1–10. https://doi.org/10.1038/s41698-018-0048-z
Yuan Y, Jiang Y-C, Sun C-K, Chen Q-M (2016) Role of the tumor microenvironment in tumor progression and the clinical applications (Review). Oncol Rep 35:2499–2515. https://doi.org/10.3892/or.2016.4660
Zekri A-RN, El-Sisi ER, Youssef ASE-D et al (2018) MicroRNA Signatures for circulating CD133-positive cells in hepatocellular carcinoma with HCV infection. PLoS ONE 13:e0193709. https://doi.org/10.1371/journal.pone.0193709
Zhu S, Hoshida Y (2018) Molecular heterogeneity in hepatocellular carcinoma. Hepat Oncol. https://doi.org/10.2217/hep-2018-0005
Zhu Q, Lu G, Luo Z et al (2018) CircRNA circ_0067934 promotes tumor growth and metastasis in hepatocellular carcinoma through regulation of miR-1324/FZD5/Wnt/β-catenin axis. Biochem Biophys Res Commun 497:626–632. https://doi.org/10.1016/j.bbrc.2018.02.119
Zhu G-Q, Yang Y, Chen E-B et al (2019) Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. J Transl Med 17:203. https://doi.org/10.1186/s12967-019-1946-8
Zucman-Rossi J, Villanueva A, Nault J-C, Llovet JM (2015) Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149:1226-1239.e4. https://doi.org/10.1053/j.gastro.2015.05.061
Acknowledgements
Not Applicable
Funding
Not applicable.
Author information
Authors and Affiliations
Contributions
AR and FH contributed to the conception of study. AR contributed in design of the study and analyzing the data. AR performed the literature review and wrote the manuscript. AR and FH contributed in revising the manuscript. All authors approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The author reports no conflicts of interest in this work.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Raja, A., Haq, F. Molecular classification of hepatocellular carcinoma: prognostic importance and clinical applications. J Cancer Res Clin Oncol 148, 15–29 (2022). https://doi.org/10.1007/s00432-021-03826-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-021-03826-w